lecture 31: emerging treatments for drug dependence: clinical evaluation Flashcards

1
Q

What are substance use definitions?

A
  • substance/drug use = sanctioned by society
  • substance/drug misuse = unsanctioned; involves risk without apparent harm
  • substance use disorder (ICD; DSM V) = drug use resulting in [harm] problems
  • substance dependence = daily physical need for the drug = homeostasis (neuroadaptation)
  • substance addiction = as above + harm/s
  • tolerance = more drug to get same effect
  • withdrawal = illness after stopping dependent use (neuroadaptation reversal)
  • intoxication = impairment associated with high dosage
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is the epidemiology of substance use disorders?

A
  • lifetime prevalence substance use disorders ~15-20%; dependence ~6-8% population
  • tobacco (nicotine dependence) ~16%
  • increasing prevalence/epidemic opioid use disorders (dependence) and opioid related deaths (analgesics)
  • alcohol use disorders:
    • lifetime risk disorder !20%
    • 25% seek medical help
    • 15-20% GP patients
    • dependence ~4% M and 2% F (~80% males, 60% females drink)
  • endemic cannabis, ATS (methamphetamine), “synthetics”, prescription psychotropics
  • overwhelming majority SUDs and addiction establish before third decade of life
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is the neurobiology of addiction?

A
  • all drugs of abuse target the brain’s pleasure centre
  • brain reward (dopamine) pathways
    • these brain circuits are important for natural rewards such as food, music and art
  • typically, dopamine increases in response to natural rewards such as food
  • when cocaine is taken, dopamine increases are exaggerated, and communication is altered
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What is seen in brain scans of a meth abuser at different time points of abstinence?

A
  • is this a brain disease
  • or an acquired condition
  • or are these people just weak?
  • changes in the brain’s signalling
  • this shows the density of dopamine receptors
  • reasonable recovery after 24 months
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is environmental neuroadaptation?

A
  • micrographs of nucleus accumbens neurons in animals exposed to nonaddictive drugs display dendritic branches with normal numbers of signal-receiving projections called spines (left and centre)
  • but those who become addicted to cocain sprout additional spines on the branches, which consequently look bushier (right)
  • presumably, such remodelling makes neurons more sensitive to signals from the VTA and elsewhere and thus contibutes to drug sensitivity
  • recent findings suggest that delta FosB plays a part in spine growth
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is the relationship between genes and addiction?

A
  • Goodwin D: Alcoholism and Genetics
  • Schickit M: sons of alcoholics
  • Van den Bree: Genetic and environmental influences on drug use and abuse/dependence in male and female twins
  • McClellan A: drug dependence, a chronic medical illness
  • Gerra G: OPRK1 polymorphism
  • Bevilacque L: genes and addictions
  • Schuckit M: alcohol use disorders
  • i.e. a lot of research
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is the bio-psycho-social model of drug dependence / addiction?

A
  • genotype + environment (Psych-soc) = phenotype
  • drugs as reinforcers of behaviour (prim/sec)
  • addiction NOT caused by single agent/event
  • addiction process analogous with other chronic diseases e.g. heart disease and diabetes
  • treatment focus: reduce mortality and morbidity
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

On what does target organ damage depend?

A
  • genes and environment
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

How do genes influence vulnerability?

A
  • genetic variation in COMT influences the harmful effects of abused drugs
  • met/met (low, equal cannabis/no cannabis use)
  • met/val (low, more cannabis use than no)
  • val/val (high cannabis use, low no use)
  • val/val more likely to suffer the harmful effects of abused drugs e.g. psychosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is the relationship between genes and treatment response?

A
  • genetics can help predict the outcome of treatment for alcohol dependence
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What kind of disease is drug addiction?

A
  • drug addiction is a chronic disease
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is a comparison of relapse rates between drug addiction and other chronic illnesses?

A
  • drug addiction: 40-60%
  • type I diabetesL 30-50%
  • hypertension: 50-70%
  • asthma: 50-70%
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

How GP “confidence” to treat illegal drug use or alcoholism compare to other chronic diseases?

A
  • hypertension: 82.8
  • diabetes: 82.3
  • depression: 44.1
  • prescription drug abuse: 30.2
  • alcoholism: 19.9
  • illegal drug use: 16.9
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is the treatment for nicotine addiction?

A
  • most smokers are “addicted”
  • QUIT strategy; CBT (relapse prevention); others including acupuncture, hypnosis, groups etc
  • nicotine replacement therapy (NRT): gum, lozenge, puffer, transdermal patch
  • relapse prevention pharmacotherapy (“anti-craving”) e.g. Varenicline, Bupropion, Cytisine
  • immunotherapy: vaccine in phase 3 trials
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What are the effects of methoxsalen on nicotine concentration and smoking desire?

A
  • desire to smoke decreases with increasing concentration of methoxsalen (30 and 30mg, 35 at 10mg)
  • increasing concentration of blood nicotine with increasing methoxsalen dosage
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What is the endogenous cannabinoid system?

A
  • CB1 (CNS) and CB2 (Immune) identified but more are likely to exist
  • CB1 agonist: (THC/CBD) products: sativex, dronabinol, for anorexia, wasting (AIDS) and nausea associated cancer (special access scheme)
  • CB1 antagonist: rimonabant appetite suppressant; antiaddiction; ?antipsychotic
  • cannabis: THC, cannabidiol/CBD, etc
  • THC addiction: treatments similar for tobacco smoking, psychosis and liver risks
  • legal THC for malignant pain, MS, epilepsy, glaucoma etc california; ?CBD
  • decriminalised THC: SA for personal use (Dutch)
  • legal highs: synthetic cannabis, kronic etc
17
Q

What is world alcohol consumption?

A
  • we are equatable with russua and america
18
Q

What is the lifetime risk of death from an alcohol related disease by number of standard drinks per day, per 100 people with that drinking pattern?

A
  • 2 standard drinks recommended
  • not daily to avoid habituating
  • reasonably strong correllation with escalation of habits
19
Q

What is a standard drink?

A
  • for healthy adults, moderate drinking = 2 standard drinks (20gm) regularly/or less (not daily)
  • unlikely harmful
  • up to 4 (40gm) infrequently unlikely harmful
  • higher dose/frequency exposures carry increasing risk
  • pregnant women and children should abstain
  • 1-2 standard drinks occasionally not likely harmful to patients with “most” medical conditions; precautions for elderly/ill, illicit drug users, high risk activities…
20
Q

What is alcohol withdrawal syndrome?

A
  • chronic drinking → downregulate GABA and upregulate glutamate (NMDA) = neuroadaptation
  • reversal of neuroadaptation = hyperadrenergic state and excess glutaminergic activity (neurotoxic)
  • complications:
    • hyperadrenergic state = hypertension, tachycardia etc
    • withdrawal seizures, delirium, hallucinosis etc
  • medical management:
    • thiamine
    • fluids
    • electrolytes
    • benzodiazepines e.g. Diazepam/Oxazepam, AWScales..
21
Q

How is alcohol (ethanol) dependence/addiction treated?

A
  • identify and manage co-morbidity (e.g. ABI)
  • rehabilitation (CBT/RP programmes; AA, RR.. etc)
  • relapse prevention/RP pharmacotherapy
    • e.g. naltrexone, acamprosate, disulfiram (Antabuse) prorgramme,
    • ?baclofen, vigabatrin, topiramate, valproate (under investigation: kappa antagonists)
    • reward drinkers have best response to naltrexone - incredibly dampens the enthusiasm/reward signalling, don’t drink to the same extent
    • acamprosate is minimally effective but works in some
    • dilsulfiram (antabuse) - if you take this tablet every night, makes you averse to alcohol, most people don’t want to take, one of the most evidence based treatments, but very low compliance so only 3-4% of alcoholics take it
22
Q

What are aspects to consider in heroin addiction?

A
  • heroin = diacetylmorphine
  • smoke, “chase”, inject
  • BBV (Hep B/C; HIV); sepsis (SBE); NB: OD Risk! (~2% annual mortality)
  • OST: methadone; buprenorphine; naltrexone formulations
  • harm minimisation: syringe exchange, support networks, injecting rooms, naloxone, drug courts: diversion programmes, ? heroin trial
  • less than 1% of the community inject
  • use to be available across the country
  • it is the injecting that is really bad
23
Q

What is seen with chronic groin injecting?

A
24
Q

What is seen with chronic leg/skin injecting?

A
25
Q

What is seen with temazepam IV and digital infarction?

A
26
Q

What is the opioid supply in australia?

A
  • oxycontin going up
  • morphine going up
27
Q

What is seen with iatrogenic addiction (pethidine)?

A
  • multiple operations for abcesses for a drug that doctors were prescribing
28
Q

How are opioid (illicit and pharmaceutical) dependence/addictions treated?

A
  • rehabilitation programmes (CBT/RP; NA etc)
  • relapse prevention pharmacotherapy: ORT
    • agonist (maintenance) therapy e.g. (Subutex) and methadone syrup; buprenorphine, buprenorphone-naloxone (suboxone)
    • antagonist therapy: e.g. naltrexone tablets with “program” or via implant; depot injection (soon)
29
Q

What is opioid replacement therapy (ORT) by replacement medications in victoria from 2000 to 2011?

A
30
Q

What is ORT with suboxone and subutex?

A
  • suboxone contains both buprenorphine and naloxone (subutex = buprenorphine alone)
  • buprenorphine is a partial agonist and therefore has less toxicity risks:
    • less overdose risk (less child poisoning)
    • less potential interaction risk
    • less sedating than methadone
  • previously an opioid analgesic, buprenorphine is now commonly used to treat opioid addiction
  • naloxone blocks the effects of opioids (short-acting)
31
Q

How are stimulant (e.g. amphetamines, cocaine) dependence/addictions treated?

A
  • rehabilitation programmes (CBT/RP; NA etc)
  • relapse prevention pharmacotherapy includes:
    • SSRI (Fluoxetine = SERT-inhibitor) for MDMA (ecstasy, etc)
    • disulfiram (?dopamine B-hydroxylase +/- paired association with ethanol)
    • topiramate: dexamphetamine substitution?
  • immunotherapy for cocaine and methamphetamine in phase 3 trials
32
Q

summary

A
  • use disorders are mostly self-limiting conditions - brief interventions
  • drug dependence/addiction is for most a chronic relapsing and remitting comorbid disease - prolonged interventions = CDM approach
  • drug dependence/addiction has a biopsychosocial aetiology and therefore requires a multidisciplinary approach to management